Oculis Highlights Positive Phase 2 Data for Privosegtor
Oculis will present Phase 2 ACUITY data for Privosegtor and detail its PIONEER registrational program in optic neuritis. The program has FDA Breakthrough Therapy and EMA PRIME designations.
Related stories
ResMed Publishes Q1 FY2027 Earnings Call Transcript
ResMed published a transcript of its Q1 fiscal 2027 earnings call.
M impact | EQUITY | Oct 30, 2026, 06:15 AM UTC
Microsoft Prices $25 Billion Senior Unsecured Notes Offering
Microsoft announced pricing for $25 billion in aggregate principal amount of senior unsecured notes.
H impact | EQUITY | Oct 30, 2026, 06:12 AM UTC
Asian session market picture: S&P 500 -0.93%, Nasdaq 100 -2%; USD/JPY -0.01%, WTI +1.32%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.93 percent, Nasdaq futures is down 2 percent, Dow futures is down 0.15 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 06:00 AM UTC
Strategy Eyes More Bitcoin Buys, Cites $30 Billion Credit Capacity
Strategy is looking to finance additional Bitcoin purchases through preferred-share offerings. Executive Chairman Michael Saylor said the company has capacity to create up to $30 b
M impact | EQUITY | Oct 30, 2026, 05:56 AM UTC
Technip Energies Flags Hormuz Logistics Risk to Middle East Projects in 2027
M impact | EQUITY | Oct 30, 2026, 05:55 AM UTC
Accenture and Unilever Partner to Scale Digital Twins Across Factories
Accenture and Unilever are partnering to scale AI-enabled digital twins across global factories.
M impact | EQUITY | Oct 30, 2026, 05:54 AM UTC